Literature DB >> 16135695

Placental expression of peroxisome proliferator-activated receptors in rat pregnancy and the effect of increased glucocorticoid exposure.

Damien P Hewitt1, Peter J Mark, Brendan J Waddell.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily of ligand-activated transcription factors. Recent gene deletion studies indicate that PPARG and PPARD play critical roles in rodent development, including effects on placental vascularization. In this study we investigated the expression of the PPAR isoforms and their heterodimeric partner, RXRA, in the two functionally and morphologically distinct zones of the rat placenta during normal gestation and after glucocorticoid-induced fetal and placental growth restriction. Real-time reverse transcription-polymerase chain reaction and immunohistochemical analysis demonstrated markedly higher expression of Ppara, Pparg, and Rxra mRNA in labyrinth zone trophoblast as compared with basal zone near term. There was also a marked increase in Pparg (65%, P < 0.05) and Ppara (91%, P < 0.05) mRNA specifically in the labyrinth zone over the final third of pregnancy. In contrast, expression of Ppard mRNA fell (P < 0.001) in both placental zones over the same period. Maternal dexamethasone treatment (1 mug/ml in drinking water; Days 13-22, term = 23 days) reduced placental (44%) and fetal (31%) weights and resulted in a fall in Pparg (37%, P < 0.05) mRNA expression specifically in the labyrinth zone at Day 22. Placental expression of Ppara, Ppard, and Rxra was unaffected by dexamethasone treatment. These data suggest that PPARG:RXRA heterodimers play important roles in labyrinth zone growth late in pregnancy, possibly supporting vascular development. Moreover, glucocorticoid inhibition of placental growth appears to be mediated, in part, via a labyrinth-zone-specific suppression of PPARG.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16135695     DOI: 10.1095/biolreprod.105.045914

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  7 in total

Review 1.  Rat placentation: an experimental model for investigating the hemochorial maternal-fetal interface.

Authors:  M J Soares; D Chakraborty; M A Karim Rumi; T Konno; S J Renaud
Journal:  Placenta       Date:  2012-01-28       Impact factor: 3.481

2.  In utero glucocorticoid exposure reduces fetal skeletal muscle mass in rats independent of effects on maternal nutrition.

Authors:  Ganga Gokulakrishnan; Irma J Estrada; Horacio A Sosa; Marta L Fiorotto
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-03-14       Impact factor: 3.619

3.  Changes in the placental glucocorticoid barrier during rat pregnancy: impact on placental corticosterone levels and regulation by progesterone.

Authors:  Peter J Mark; Sheldon Augustus; Jessica L Lewis; Damien P Hewitt; Brendan J Waddell
Journal:  Biol Reprod       Date:  2009-02-04       Impact factor: 4.285

4.  Inhibition of PPARγ during rat pregnancy causes intrauterine growth restriction and attenuation of uterine vasodilation.

Authors:  Natalia I Gokina; Siu-Lung Chan; Abbie C Chapman; Karen Oppenheimer; Thomas L Jetton; Marilyn J Cipolla
Journal:  Front Physiol       Date:  2013-07-23       Impact factor: 4.566

5.  Maternal Tobacco Smoke Exposure Causes Sex-Divergent Changes in Placental Lipid Metabolism in the Rat.

Authors:  Claudia Weinheimer; Haimei Wang; Jessica M Comstock; Purneet Singh; Zhengming Wang; Brent A Locklear; Kasi L Goodwin; J Alan Maschek; James E Cox; Michelle L Baack; Lisa A Joss-Moore
Journal:  Reprod Sci       Date:  2020-01-06       Impact factor: 3.060

6.  PPAR Signaling in Placental Development and Function.

Authors:  Yaacov Barak; Yoel Sadovsky; Tali Shalom-Barak
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

7.  PPAR Action in Human Placental Development and Pregnancy and Its Complications.

Authors:  Fritz Wieser; Leslie Waite; Christophe Depoix; Robert N Taylor
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.